Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
 
  
   
Insider Information:   Foletta Mark G
Relationship:   EVP & Chief Financial ...
City:   San Diego
State:   CA
   
Insider Summary:
  
   
Companies Owned :   5    
Direct Shares   110,179    

Indirect Shares

   62,398      
Direct Value   $1,139,767    

Indirect Value

   $7,947,633      
Total Shares   172,577      
Total Value   $9,087,400      


DexCom Inc $378,671 Regulus Therapeutics Inc. $165,458 AMN Healthcare Services Inc $576,685 Forte Biosciences Inc $18,953 DexCom Inc $378,671 Regulus Therapeutics Inc. $165,458 AMN Healthcare Services Inc $576,685 Forte Biosciences Inc $18,953
 


Historical Performance :
Based on 6 Month Return Percentages
Buys 
Sells 

     Total Filings :
    1   
    1    

     Stock price went up :
    1   
    1    
     Stock price went down :
    0   
    0    
   
     Gain/Loss Ratio :
   1.0   
   1.0   
     Percentage Gain/Loss :
   0.7%
 13.5%
     
   
Holdings :
     Menu Company Name Ticker Relation Direct Date Direct Shares Indirect Date Indirect Shares Total Value Sold  
            Amylin Pharmaceuticals Inc AMLN SVP, Chief Financial O... 2012-08-08 0 2012-08-08 0    Premium*  
            DexCom Inc DXCM Director 2024-05-22 2,973 2024-05-22 62,398    Premium*  
            Regulus Therapeutics Inc. RGLS Director 2017-12-04 81,910 2015-08-13 0    Premium*  
            AMN Healthcare Services Inc AHS Director 2024-04-19 10,254 2016-04-20 0    Premium*  
            Forte Biosciences Inc FBRX EVP & Chief Financial ... 2019-05-28 15,042 2017-04-19 0    Premium*  
* Premium Members only  

Records found :    144         Free Registration Required For Full Results.    Limit: 25

 Download
  Page 4 of 6
Ticker Company Name Relation   Off-Dir-10% Trans. Date Form Action Price Mkt Value D/I Shares    Holdings   
Rank

  
3m +/-  
Form
AMLN Amylin Pharmaceuticals In... Senior VP, Finance & CFO   •       –      –    2007-08-31 4 OE $13.25 $39,750 D/D 3,000 26,242 0 -
AMLN Amylin Pharmaceuticals In... Senior VP, Finance & CFO   •       –      –    2007-08-31 4 AS $48.86 $146,575 D/D (3,000) 23,242 0 -
AMLN Amylin Pharmaceuticals In... Senior VP, Finance & CFO   •       –      –    2007-09-28 4 AS $49.98 $149,932 D/D (3,000) 23,242 0 -
AMLN Amylin Pharmaceuticals In... Senior VP, Finance & CFO   •       –      –    2007-09-28 4 OE $13.25 $39,750 D/D 3,000 26,242 0 -
AMLN Amylin Pharmaceuticals In... Senior VP, Finance & CFO   •       –      –    2008-02-01 4 A $37.00 $6,734 D/D 182 23,753 0 -
AMLN Amylin Pharmaceuticals In... Sr VP Finance & CFO   •       –      –    2009-02-03 4 A $11.80 $6,903 D/D 585 24,839 0 -
AMLN Amylin Pharmaceuticals In... Sr VP Finance & CFO   •       –      –    2009-03-04 4 A $0.00 $0 I/I 2,550 3,455 0 -
AMLN Amylin Pharmaceuticals In... SVP Chief Financial Officer   •       –      –    2010-02-03 4 A $0.00 $0 I/I 1,360 4,815 0 -
AMLN Amylin Pharmaceuticals In... SVP Chief Financial Officer   •       –      –    2010-02-03 4 A $17.83 $7,346 D/D 412 26,412 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial Officer   •       –      –    2010-04-06 4 OE $13.25 $8,454 D/D 638 28,138 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial Officer   •       –      –    2011-03-01 4 A $0.00 $0 D/D 15,000 41,457 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial Officer   •       –      –    2011-03-01 4 A $0.00 $0 I/I 1,630 6,445 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial Officer   •       –      –    2011-12-31 5 D $0.00 $0 D/D (488) 41,699 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial Officer   •       –      –    2012-01-10 4 A $0.00 $0 D/D 7,500 49,687 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial Officer   •       –      –    2012-02-08 4 D $16.47 $51,419 D/D (3,122) 54,565 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial Officer   •       –      –    2012-02-08 4 A $0.00 $0 D/D 8,000 57,687 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial OfficerSV   •       –      –    2012-03-01 4 S $17.11 $31,585 D/D (1,846) 62,490 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial OfficerSV   •       –      –    2012-03-06 4 A $0.00 $0 I/I 1,529 7,974 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial OfficerSV   •       –      –    2012-03-06 4 A $0.00 $0 D/D 10,000 72,490 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial OfficerSV   •       –      –    2012-07-25 4 A $14.62 $12,866 D/D 880 73,370 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial OfficerSV   •       –      –    2012-08-08 4 D $31.00 $2,274,470 D/D (73,370) 64,702 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial OfficerSV   •       –      –    2012-08-08 4 A $31.00 $2,005,762 D/D 64,702 138,072 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial OfficerSV   •       –      –    2012-08-08 4 D $31.00 $370,531 I/I (11,953) 0 0 -
AMLN Amylin Pharmaceuticals In... SVP, Chief Financial OfficerSV   •       –      –    2012-08-08 4 D $31.00 $2,005,762 D/D (64,702) 0 0 -
DXCM DexCom Inc Director   –       •      –    2014-11-17 4 A $0.00 $7 D/D 7,322 7,322 0 -
  144  Records found
  1   2   3   4  5   6      
  Page 4 of 6  
 
Free Registration Required For Full Results.    Limit: 25

 
 
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
OE - Options Exercised A - Aquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us